Following stroke or TIA can patient screening & enhanced risk factor management prevent subsequent memory decline.

Not Applicable

Completed

• Conditions: Topic: Stroke; Subtopic: Prevention; Disease: Therapy type; Circulatory System

• Registration Number: ISRCTN42688361
• Lead Sponsor: orfolk and Norwich University Hospital NHS Trust

Brief Summary

2020 results in https://pubmed.ncbi.nlm.nih.gov/32943015/ (added 21/09/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-16
• Study Completion: 2018-12-31
• Last Update Posted: 5 October 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 167

Inclusion Criteria

All adult patients admitted to the participating centre with confirmed stroke (first/recurrent) or TIA will be considered for the trial.
Inclusion criteria
1. Normal cognition (MoCA score >=26) and no evidence of moderate/severe depression (GDS <9). Patients with normal cognition (MoCA score >=26) will be informed of their normal cognition status and will be managed routinely by the clinicians with regards to their risk factors. They will be invited to participate in the observational study (defined as GROUP O). If they agree, written informed consent will be obtained.
2. Intermediate cognition (MoCA score 20-25). Patients with MoCA score of 20-25 will be informed of their cognitive status and be invited to participate in the feasibility trial. Those who agree and provide written informed consent will be randomised into one of two groups; control arm (GROUP C) and intervention arm (GROUP I).

Exclusion Criteria

Those with following conditions will be excluded on ethical grounds:
1. Severe cognitive deficit (MoCA <20). Patients with severe cognitive deficit (MoCA <20) will be informed of their cognition status and their GP will also be informed for further appropriate action. Hospital teams will be liaised with and an appropriate level of community support at discharge will be organised. By doing so, we hope that the anxiety of knowing their cognitive deficit will be reduced. They will be excluded from the trial as it is not ethical to include them in the feasibility stage.
2. Established Dementia / MoCA score <20
3. Moderate/severe depression
4. Life expectancy <1 yr (e.g. severe stroke/terminal cancer)
5. Unable to perform MoCA (aphasic patients)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Cognition and in CV risk factors over 1 year follow-up; Timepoint(s): Changes in Cognition and in CV risk factors over 1 year follow-up